通知要求，深入实施自由贸易试验区提升战略，用好上海自由贸易试验区制度型开放试点经验，因 地制宜做好复制推广工作，重点推进企业和群众急需的试点举措，在更大范围释放制度创新红利，以高 水平开放推动深层次改革、高质量发展。 【纠错】 【责任编辑:邱丽芳】 通知指出，2023年11月，国务院印发《全面对接国际高标准经贸规则推进中国（上海）自由贸易试 验区高水平制度型开放总体方案》，支持上海自由贸易试验区全面对接国际高标准经贸规则开展先行先 试，打造国家制度型开放示范区。经过一年多的试点试验，开展了一批引领性、标志性制度创新，形成 了一批具有较高含金量的先进经验和典型案例。 新华社北京7月3日电（记者谢希瑶）国务院日前印发的《关于做好自由贸易试验区全面对接国际高 标准经贸规则推进高水平制度型开放试点措施复制推广工作的通知》3日对外发布。 根据通知，此次复制推广的77条试点措施，涵盖服务贸易、货物贸易、数字贸易、知识产权保护、 政府采购改革、"边境后"管理制度改革、风险防控等7个方面。其中，加强数字人民币试点应用场景创 新、优化跨国公司跨境资金集中运营管理政策、制定数据出境负面清单、推动电子提单等电子单据应 用、健全协调 ...

Core Viewpoint - The Ministry of Commerce supports the establishment of a negative list for data export in free trade zones, aimed at facilitating efficient and secure cross-border data flow for enterprises [1] Group 1: Policy Measures - The recent announcement includes 77 pilot measures that cover a wide range of areas and demonstrate significant openness [1] - The Ministry of Commerce plans to accelerate the implementation of these measures to ensure they yield effective results [1] Group 2: Data Export Regulations - The negative list for data export will allow data outside the list to be exported without the need for safety assessments, standard contracts, or protective certifications [1] - This initiative is designed to meet the cross-border data flow needs of enterprises, promoting efficient and secure data movement [1]

Group 1 - Beijing is focusing on the medical sector's needs by developing a second negative list for medical devices, following the first list that included five fields [1] - The city has established a comprehensive reform system for cross-border data flow, aiming to upgrade from the initial version to a more efficient and secure model [1][2] - The second negative list will include five sectors: medical devices, intelligent connected vehicles, trade logistics, banking, and public funds, expanding the coverage of the policy [2] Group 2 - A pilot program for the negative list will be implemented on a case-by-case basis for medical enterprises, with several companies already expressing interest in participation [3] - The focus will be on enhancing data flow for research collaboration, drug development, and multi-center consultations, encouraging partnerships between local hospitals and multinational pharmaceutical companies [3]